HRL Holdings Limited

Level 8 Waterfront Place, 1 Eagle Street Brisbane Queensland 4000, Australia

GPO Box 216‌‌

Brisbane Queensland 4001, Australia

Tel +61 7 3105 5960

Email admin@hrlholdings.com

ASX Announcement 30 November 2017

Appendix 3B and Section 708A(5)(e) Notice

Please find attached an Appendix 3B in relation to the issue of the following securities as initially announced to the market on 16 October 2017 and approved by shareholders at the AGM held on 23 November 2017:

  • The issue of 60,951,485 fully paid ordinary shares in relation to the acquisition of the Analytica Laboratories business by the company following approval, for the issue of the shares as part of the acquisition price, at the AGM held on 23 November 2017.

Notice given under Section 708A(5)(e) of the Corporations Act 2001

The ordinary shares are part of a class of securities quoted on the Australian Securities Exchange. The shares were issued without disclosure to the investor under Part 6D.2, in reliance on Section 708A(5)(e) of the Corporations Act 2001.

The Company, as at the date of this notice, has complied with:

  1. The provisions of Chapter 2M of the Corporations Act 2001; and

  2. Section 674 of the Corporations Act 2001.

There is no excluded information (as defined in Section 708A(7) of the Corporations Act 2001) as at the date of this notice.

Paul Marshall Company Secretary HRL Holdings Ltd

Appendix 3B New issue announcement

Appendix 3B

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

New issue announcement, application for quotation of additional securities‌ and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

HRL Holdings Limited

ABN

99 120 896 371

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1

+Class of +securities issued or to be issued

Fully paid ordinary shares

2

Number of +securities issued or to be issued (if known) or maximum number which may be issued

60,951,485

3

Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid

+securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Fully paid ordinary shares

Error! Unknown document property name.

+ See chapter 19 for defined terms.

04/03/2013 Appendix 3B Page 2

4

Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

If the additional securities do not rank equally, please state:

  • the date from which they do

  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Yes

5

Issue price or consideration

$0.085 per share

The number of Consideration Shares to be issued to the Analytica Vendors was calculated as follows:

N = [5,700,000/FX] / 0.085

Where:

N is the number of Consideration Shares to be issued; and FX is the foreign exchange rate of New Zealand Dollars to Australian Dollars (which was 1.1002).

6

Purpose of the issue

(If issued as consideration for the acquisition of assets, clearly identify those assets)

The shares were issued as part of the consideration for the acquisition of the Analytica Laboratories business as approved at the AGM held on 23 November 2017.

6a

Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

No

6b

The date the security holder resolution under rule 7.1A was passed

6c

Number of +securities issued without security holder approval under rule 7.1

6d

Number of +securities issued with security holder approval under rule 7.1A

6e

Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

6f

Number of securities issued under an exception in rule 7.2

6g

If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.

6h

If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

6i

Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A - complete Annexure 1 and release to ASX Market Announcements

7

+Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

30 November 2017

Number

+Class

493,402,627

Fully paid ordinary shares

8 Number and +class of all

+securities quoted on ASX (including the securities in section 2 if applicable

HRL Holdings Ltd. published this content on 30 November 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 30 November 2017 05:36:07 UTC.

Original documenthttp://www.hrlholdings.com/wp-content/uploads/2017/11/HRL-ASX-30-Nov-2017-Analytica-3B-S708.pdf

Public permalinkhttp://www.publicnow.com/view/E016C5E66817CE066A8650891531E1A912FE72C9